Ferdinando Squitieri

List of Publications by Year
in descending order

187 papers	13,502 citations	28190 55 h-index	24179 110 g-index
191 all docs	191 docs citations	191 times ranked	12913 citing authors

#	Article	IF	Citations
1	Cognitive Reserve in Early Manifest Huntington Disease Patients: Leisure Time Is Associated with Lower Cognitive and Functional Impairment. Journal of Personalized Medicine, 2022, 12, 36.	1.1	7
2	â€œSpazio Huntingtonâ€: Tracing the Early Motor, Cognitive and Behavioral Profiles of Kids with Proven Pediatric Huntington Disease and Expanded Mutations > 80 CAG Repeats. Journal of Personalized Medicine, 2022, 12, 120.	1.1	1
3	Sleep Quality and Related Clinical Manifestations in Huntington Disease. Journal of Personalized Medicine, 2022, 12, 864.	1.1	5
4	Abnormal visual scanning and impaired mental state recognition in pre-manifest Huntington disease. Experimental Brain Research, 2021, 239, 141-150.	0.7	6
5	A Novel Triplet-Primed PCR Assay to Detect the Full Range of Trinucleotide CAG Repeats in the Huntingtin Gene (HTT). International Journal of Molecular Sciences, 2021, 22, 1689.	1.8	8
6	Compensating for verbal-motor deficits in neuropsychological assessment in movement disorders: sensitivity and specificity of the ECAS in Parkinsonâ€™s and Huntingtonâ€™s diseases. Neurological Sciences, 2021, 42, 4997-5006.	0.9	5
7	Validity of the Italian multiple sclerosis neuropsychological screening questionnaire. Neurological Sciences, 2021, 42, 4583-4589.	0.9	2
8	Cognitive and behavioral associated changes in manifest Huntington disease: A retrospective crossâ€sectional study. Brain and Behavior, 2021, 11, e02151.	1.0	12
9	Perceptions about Research Participation among Individuals at Risk and Individuals with Premanifest Huntingtonâ€™s Disease: A Survey Conducted by the European Huntington Association. Journal of Personalized Medicine, 2021, 11, 815.	1.1	4
10	Known Drugs Identified by Structure-Based Virtual Screening Are Able to Bind Sigma-1 Receptor and Increase Growth of Huntington Disease Patient-Derived Cells. International Journal of Molecular Sciences, 2021, 22, 1293.	1.8	5
11	Modeling Manifest Huntingtonâ€™s Disease Prevalence Using Diagnosed Incidence and Survival Time. Neuroepidemiology, 2021, 55, 361-368.	1.1	15
12	Arithmetic Word-Problem Solving as Cognitive Marker of Progression in Pre-Manifest and Manifest Huntingtonâ€™s Disease. Journal of Huntington's Disease, 2021, 10, 1-10.	0.9	2
13	Sorcin is an early marker of neurodegeneration, Ca2+ dysregulation and endoplasmic reticulum stress associated to neurodegenerative diseases. Cell Death and Disease, 2020, 11, 861.	2.7	29
14	Tracing the mutated HTT and haplotype of the African ancestor who spread Huntington disease into the Middle East. Genetics in Medicine, 2020, 22, 1903-1908.	1.1	8
15	Frequency of the loss of CAA interruption in the HTT CAG tract and implications for Huntington disease in the reduced penetrance range. Genetics in Medicine, 2020, 22, 2108-2113.	1.1	32
16	Incidence and prevalence of Huntington disease (HD) in the Sultanate of Oman: the first Middle East post-HTT service-based study. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1359-1360.	0.9	3
17	Mitochondrial Respiration Changes in R6/2 Huntingtonâ€™s Disease Model Mice during Aging in a Brain Region Specific Manner. International Journal of Molecular Sciences, 2020, 21, 5412.	1.8	12
18	Utility of the Parkinsonâ€™s disease-Cognitive Rating Scale for the screening of global cognitive status in Huntingtonâ€™s disease. Journal of Neurology, 2020, 267, 1527-1535.	1.8	13

#	Article	IF	Citations
19	Emotion recognition and inhibitory control in manifest and pre-manifest Huntington's disease: evidence from a new Stroop task. Neural Regeneration Research, 2020, 15, 1518.	1.6	4
20	DNA damage signatures in peripheral blood cells as biomarkers in prodromal huntington disease. Annals of Neurology, 2019, 85, 296-301.	2.8	28
21	Generation of induced pluripotent stem cell line CSSi008-A (4698) from a patient affected by advanced stage of Dentato-Rubral-Pallidoluysian atrophy (DRPLA). Stem Cell Research, 2019, 40, 101551.	0.3	8
22	International Guidelines for the Treatment of Huntington's Disease. Frontiers in Neurology, 2019, 10, 710.	1.1	98
23	Length of Uninterrupted CAG, Independent of Polyglutamine Size, Results in Increased Somatic Instability, Hastening Onset of Huntington Disease. American Journal of Human Genetics, 2019, 104, 1116-1126.	2.6	130
24	Genetic Counseling in Huntington's Disease: Potential New Challenges on Horizon?. Frontiers in Neurology, 2019, 10, 453.	1.1	31
25	Assessment of the Performance of a Modified Motor Scale as Applied to Juvenile Onset Huntingtonâ€™s Disease. Journal of Huntington's Disease, 2019, 8, 181-193.	0.9	6
26	Defining pediatric huntington disease: Time to abandon the term Juvenile Huntington Disease?. Movement Disorders, 2019, 34, 584-585.	2.2	16
27	A Comprehensive Haplotype-Targeting Strategy for Allele-Specific HTT Suppression in Huntington Disease. American Journal of Human Genetics, 2019, 105, 1112-1125.	2.6	23
28	Safer Attitude to Risky Decision-Making in Premanifest Huntingtonâ€™s Disease Subjects. Frontiers in Psychology, 2019, 10, 846.	1.1	3
29	Task-switching abilities in pre-manifest Huntington's disease subjects. Parkinsonism and Related Disorders, 2019, 60, 111-117.	1.1	15
30	Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study. Lancet Neurology, The, 2019, 18, 165-176.	4.9	82
31	Effects of stimulus-related variables on mental states recognition in Huntingtonâ€™s disease. International Journal of Neuroscience, 2019, 129, 563-572.	0.8	6
32	Emotional processing in RRMS patients: Dissociation between behavioural and neurophysiological response. Multiple Sclerosis and Related Disorders, 2019, 27, 344-349.	0.9	16
33	CM-Pf deep brain stimulation and the long term management of motor and psychiatric symptoms in a case of Tourette syndrome. Journal of Clinical Neuroscience, 2019, 62, 269-272.	0.8	12
34	Clinical and genetic characteristics of late-onset Huntington's disease. Parkinsonism and Related Disorders, 2019, 61, 101-105.	1.1	17
35	Exploring emotion regulation and emotion recognition in people with presymptomatic Huntington's disease: The role of emotional awareness. Neuropsychologia, 2018, 112, 1-9.	0.7	29
36	The molecular epidemiology of Huntington disease is related to intermediate allele frequency and haplotype in the general population. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2018, 177, 346-357.	1.1	60

#	Article	IF	Citations
37	Generation of induced pluripotent stem cell line, CSSi004-A (2962), from a patient diagnosed with Huntington's disease at the presymptomatic stage. Stem Cell Research, 2018, 28, 145-148.	0.3	7
38	Generation of induced pluripotent stem cell line, CSSi002-A (2851), from a patient with juvenile Huntington Disease. Stem Cell Research, 2018, 27, 86-89.	0.3	5
39	The contribution of gender differences in motor, behavioral and cognitive features to functional capacity, independence and quality of life in patients with Huntington's disease. Parkinsonism and Related Disorders, 2018, 49, 42-47.	1.1	46
40	Generation of the induced pluripotent stem cell line CSSi006-A (3681) from a patient affected by advanced-stage Juvenile Onset Huntington's Disease. Stem Cell Research, 2018, 29, 174-178.	0.3	1
41	Executive functioning in relapsing-remitting multiple sclerosis patients without cognitive impairment: A task-switching protocol. Multiple Sclerosis Journal, 2018, 24, 1328-1336.	1.4	15
42	F13â€...Assessment of the performance of a modified motor scale as applied to juvenile onset huntingtonâ€™s disease. , 2018, , .		0
43	H01â€...Upcoming international guidelines in huntingtonâ€™s disease. , 2018, , .		0
44	B18â€...Human induced neural stem cells as model to study the neural development in huntingtonâ€™s disease. , 2018, , .		0
45	F34â€...Game of dice task performance in premanifest huntingtonâ€™s disease subjects. , 2018, , .		0
46	Biological and clinical manifestations of juvenile Huntington's disease: a retrospective analysis. Lancet Neurology, The, 2018, 17, 986-993.	4.9	115
47	Optical coherence tomography (OCT) study in Argentinean Huntingtonâ€™s disease patients. International Journal of Neuroscience, 2018, 128, 1157-1162.	0.8	22
48	Reduced Cancer Incidence in Huntington's Disease: Analysis in the Registry Study. Journal of Huntington's Disease, 2018, 7, 209-222.	0.9	14
49	F02â€...A cluster of HD in italy with several subjects carrying cag expansion homozygousity in different generations and genetic risk over 50%. , 2018, , .		0
50	F75â€...A huntingtonâ€™s disease (HD) database at lirh foundation (LIRH-rome site): enroll-hd study as a starting point. , 2018, , .		0
51	F33â€...Task-switching abilities in pre-manifest huntingtonâ€™s disease subjects. , 2018, , .		0
52	A22â€...Sorcin rescues ca (II) dysregulation and endoplasmic reticulum stress in huntingtonâ€™s disease. , 2018, , .		0
53	Glucose transportation in the brain and its impairment in Huntington disease: one more shade of the energetic metabolism failure?. Amino Acids, 2017, 49, 1147-1157.	1.2	20
54	Restingâ€state connectivity and modulated somatomotor and defaultâ€mode networks in Huntington disease. CNS Neuroscience and Therapeutics, 2017, 23, 488-497.	1.9	19

#	Article	IF	Citations
55	Polyglutamine tracts regulate beclin 1-dependent autophagy. Nature, 2017, 545, 108-111.	13.7	288
56	Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study. Lancet Neurology, The, 2017, 16, 701-711.	4.9	248
57	Polyglutamine tracts regulate autophagy. Autophagy, 2017, 13, 1613-1614.	4.3	23
58	Phosphorylation of huntingtin at residue T3 is decreased in Huntingtonâ€™s disease and modulates mutant huntingtin protein conformation. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E10809-E10818.	3.3	63
59	Polyglutamine expansion affects huntingtin conformation in multiple Huntingtonâ€™s disease models. Scientific Reports, 2017, 7, 5070.	1.6	32
60	Early enteric neuron dysfunction in mouse and human HuntingtonÂdisease. Parkinsonism and Related Disorders, 2017, 34, 73-74.	1.1	12
61	Cognitive Impairment in Relapsing-Remitting Multiple Sclerosis Patients with Very Mild Clinical Disability. Behavioural Neurology, 2017, 2017, 1-10.	1.1	67
62	Letter re: Huntington disease reduced penetrance alleles occur at high frequency in the general population. Neurology, 2017, 88, 334-334.	1.5	0
63	Juvenile Huntington disease in Argentina. Arquivos De Neuro-Psiquiatria, 2016, 74, 50-54.	0.3	11
64	Major Superficial White Matter Abnormalities in Huntington's Disease. Frontiers in Neuroscience, 2016, 10, 197.	1.4	51
65	Epidemiology of Huntington disease: first postâ€‹<scp>HTT</scp> gene analysis of prevalence in Italy. Clinical Genetics, 2016, 89, 367-370.	1.0	38
66	Terapeutic Potential of Microencapsulated Sertoli Cells in Huntington Disease. CNS Neuroscience and Therapeutics, 2016, 22, 686-690.	1.9	19
67	Pridopidine, a dopamine stabilizer, improves motor performance and shows neuroprotective effects in Huntington disease R6/2 mouse model. Journal of Cellular and Molecular Medicine, 2015, 19, 2540-2548.	1.6	62
68	Antidopaminergic Medication is Associated with More Rapidly Progressive Huntingtonâ€™s Disease. Journal of Huntington's Disease, 2015, 4, 131-140.	0.9	10
69	Ethyl-eicosapentaenoic acid treatment in Huntington's disease: A placebo-controlled clinical trial. Movement Disorders, 2015, 30, 1426-1429.	2.2	33
70	Profile of pridopidine and its potential in the treatment of Huntington disease: the evidence to date. Drug Design, Development and Therapy, 2015, 9, 5827.	2.0	15
71	The Corticospinal Tract in Huntington's Disease. Cerebral Cortex, 2015, 25, 2670-2682.	1.6	33
72	Huntingtin Haplotypes Provide Prioritized Target Panels for Allele-specific Silencing in Huntington Disease Patients of European Ancestry. Molecular Therapy, 2015, 23, 1759-1771.	3.7	73

#	Article	IF	Citations
73	The role of iron in gray matter degeneration in Huntington's disease: A magnetic resonance imaging study. Human Brain Mapping, 2015, 36, 50-66.	1.9	38
74	Nitric Oxide Dysregulation in Platelets from Patients with Advanced Huntington Disease. PLoS ONE, 2014, 9, e89745.	1.1	19
75	Deep White Matter in Huntington's Disease. PLoS ONE, 2014, 9, e109676.	1.1	41
76	MRI measures of corpus callosum iron and myelin in early Huntington's disease. Human Brain Mapping, 2014, 35, 3143-3151.	1.9	42
77	Assessment Of The Huntington Quality Of Life Instrument (H-QOL-I) Cross-Cultural Validity. Value in Health, 2014, 17, A567.	0.1	3
78	Assessment Of The Huntington Clinical Self-Reported Instrument (H-CSRI) Cross-Cultural Validity. Value in Health, 2014, 17, A567.	0.1	0
79	FTY720 (fingolimod) is a neuroprotective and disease-modifying agent in cellular and mouse models of Huntington disease. Human Molecular Genetics, 2014, 23, 2251-2265.	1.4	84
80	Psychiatric onset and late chorea in a patient with 41 CAG repeats in the TATA-binding protein gene. Parkinsonism and Related Disorders, 2014, 20, 678-679.	1.1	13
81	Seeking huntington disease biomarkers by multimodal, crossâ€sectional basal ganglia imaging. Human Brain Mapping, 2013, 34, 1625-1635.	1.9	60
82	Further evidence of reliability and validity of the Huntingtonâ€™s disease quality of life battery for carers: Italian and French translations. Quality of Life Research, 2013, 22, 1093-1098.	1.5	8
83	A Randomized, Double-blind, Placebo-Controlled Study of Latrepirdine in Patients With Mild to Moderate Huntington Disease. JAMA Neurology, 2013, 70, 25.	4.5	53
84	'Fifty shades of grey' in the Huntington disease gene. Nature Reviews Neurology, 2013, 9, 421-422.	4.9	13
85	The influence of gender on phenotype and disease progression in patients with Huntington's disease. Parkinsonism and Related Disorders, 2013, 19, 192-197.	1.1	96
86	Candidate glutamatergic and dopaminergic pathway gene variants do not influence Huntingtonâ€™s disease motor onset. Neurogenetics, 2013, 14, 173-179.	0.7	10
87	The personal experience of parenting a child with Juvenile Huntingtonâ€™s Disease: perceptions across Europe. European Journal of Human Genetics, 2013, 21, 1042-1048.	1.4	19
88	Structural MRI in Huntington's disease and recommendations for its potential use in clinical trials. Neuroscience and Biobehavioral Reviews, 2013, 37, 480-490.	2.9	81
89	Recommendations for the predictive genetic test in Huntington's disease. Clinical Genetics, 2013, 83, 221-231.	1.0	175
90	Managing juvenile Huntingtonâ€™s disease. Neurodegenerative Disease Management, 2013, 3, 267-276.	1.2	78

#	Article	IF	Citations
91	One-year safety and tolerability profile of pridopidine in patients with Huntington disease. Neurology, 2013, 80, 1086-1094.	1.5	19
92	18F-fluorodeoxyglucose-PET as a biomarker in Huntingtonâ€™s disease. Neurodegenerative Disease Management, 2013, 3, 489-491.	1.2	0
93	Changes of peripheral TGF-Î²1 depend on monocytes-derived macrophages in Huntington disease. Molecular Brain, 2013, 6, 55.	1.3	26
94	Tractography of the Corpus Callosum in Huntingtonâ€™s Disease. PLoS ONE, 2013, 8, e73280.	1.1	56
95	Multimodal MRI Analysis of the Corpus Callosum Reveals White Matter Differences in Presymptomatic and Early Huntington's Disease. Cerebral Cortex, 2012, 22, 2858-2866.	1.6	64
96	Validation of the first quality-of-life measurement for patients with Huntingtonâ€™s disease. International Clinical Psychopharmacology, 2012, 27, 208-214.	0.9	15
97	CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion. Neurology, 2012, 78, 690-695.	1.5	303
98	Population stratification may bias analysis of PGC-1Î± as a modifier of age at Huntington disease motor onset. Human Genetics, 2012, 131, 1833-1840.	1.8	26
99	TAA repeat variation in the GRIK2 gene does not influence age at onset in Huntingtonâ€™s disease. Biochemical and Biophysical Research Communications, 2012, 424, 404-408.	1.0	20
100	Huntington's disease: How intermediate are intermediate repeat lengths?. Movement Disorders, 2012, 27, 1714-1717.	2.2	42
101	18F-FDG PET uptake in the pre-Huntington disease caudate affects the time-to-onset independently of CAG expansion size. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 1030-1036.	3.3	60
102	Common SNP-Based Haplotype Analysis of the 4p16.3 Huntington Disease Gene Region. American Journal of Human Genetics, 2012, 90, 434-444.	2.6	60
103	Current Pharmacological Management in Juvenile Huntingtonâ€™s Disease. PLOS Currents, 2012, 4, RRN1304.	1.4	9
104	Truncated Peroxisome Proliferator-Activated Receptor-Î³ Coactivator 1Î± Splice Variant Is Severely Altered in Huntingtonâ€™s Disease. Neurodegenerative Diseases, 2011, 8, 496-503.	0.8	32
105	Whole body cholesterol metabolism is impaired in Huntington's disease. Neuroscience Letters, 2011, 494, 245-249.	1.0	75
106	Early defect of transforming growth factor Î²1 formation in Huntingtonâ€™s disease. Journal of Cellular and Molecular Medicine, 2011, 15, 555-571.	1.6	64
107	Seeking Brain Biomarkers for Preventive Therapy in Huntington Disease. CNS Neuroscience and Therapeutics, 2011, 17, 368-386.	1.9	21
108	Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Neurology, The, 2011, 10, 1049-1057.	4.9	157

#	Article	IF	Citations
109	Genotype-, aging-dependent abnormal caspase activity in Huntington disease blood cells. Journal of Neural Transmission, 2011, 118, 1599-1607.	1.4	15
110	What is the impact of education on Huntington's disease?. Movement Disorders, 2011, 26, 1489-1495.	2.2	34
111	Caudate glucose hypometabolism in a subject carrying an unstable allele of intermediate CAG₃₃ repeat length in the Huntington's disease gene. Movement Disorders, 2011, 26, 925-927.	2.2	24
112	PET translates neurophysiology into images: A review to stimulate a network between neuroimaging and basic research. Journal of Cellular Physiology, 2011, 226, 948-961.	2.0	16
113	Discriminant Analysis of Beck Depression Inventory and Hamilton Rating Scale for Depression in Huntington's Disease. Journal of Neuropsychiatry and Clinical Neurosciences, 2011, 23, 399-402.	0.9	22
114	Factor analysis of behavioural symptoms in Huntington's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 411-412.	0.9	38
115	Key role of nuclear medicine in seeking biomarkers of Huntingtonâ€™s disease. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 1124-1127.	3.3	13
116	Abnormal morphology of peripheral cell tissues from patients with Huntington disease. Journal of Neural Transmission, 2010, 117, 77-83.	1.4	55
117	Novel T719P AÎ²PP Mutation Unbalances the Relative Proportion of Amyloid-Î² Peptides. Journal of Alzheimer's Disease, 2009, 18, 295-303.	1.2	27
118	Impaired PGC-1Î± function in muscle in Huntington's disease. Human Molecular Genetics, 2009, 18, 3048-3065.	1.4	215
119	Riluzole protects Huntington disease patients from brain glucose hypometabolism and grey matter volume loss and increases production of neurotrophins. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 1113-1120.	3.3	52
120	DNA instability in replicating Huntington's disease lymphoblasts. BMC Medical Genetics, 2009, 10, 11.	2.1	24
121	Four novel SPG3A/atlastin mutations identified in autosomal dominant hereditary spastic paraplegia kindreds with intraâ€familial variability in age of onset and complex phenotype. Clinical Genetics, 2009, 75, 485-489.	1.0	21
122	Huntington disease in subjects from an Israeli Karaite community carrying alleles of intermediate and expanded CAG repeats in the HTT gene: Huntington disease or phenocopy?. Journal of the Neurological Sciences, 2009, 277, 143-146.	0.3	44
123	Distinct Brain Volume Changes Correlating with Clinical Stage, Disease Progression Rate, Mutation Size, and Age at Onset Prediction as Early Biomarkers of Brain Atrophy in Huntington's Disease. CNS Neuroscience and Therapeutics, 2009, 15, 1-11.	1.9	69
124	De novo seven extra repeat expanded mutation in the PRNP gene in an Italian patient with early onset dementia. BMJ Case Reports, 2009, 2009, bcr0820080711-bcr0820080711.	0.2	2
125	Aripiprazole in the treatment of Huntington's disease: a case series. Neuropsychiatric Disease and Treatment, 2009, 5, 1-4.	1.0	34
126	Neuroprotective effects of riluzole in Huntingtonâ€™s disease. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 221-222.	3.3	9

#	Article	IF	Citations
127	Different spectra of genomic deletions within the CCM genes between Italian and American CCM patient cohorts. Neurogenetics, 2008, 9, 25-31.	0.7	33
128	Molecular medicine: predicting and preventing Huntingtonâ€™s disease. Neurological Sciences, 2008, 29, 205-207.	0.9	5
129	ZPLD1 gene is disrupted in a patient with balanced translocation that exhibits cerebral cavernous malformations. Neuroscience, 2008, 155, 345-349.	1.1	30
130	Aripiprazole in the treatment of Huntington’s disease: a case series. Neuropsychiatric Disease and Treatment, 2008, , 1.	1.0	19
131	ATP13A2 missense mutations in juvenile parkinsonism and young onset Parkinson disease. Neurology, 2007, 68, 1557-1562.	1.5	312
132	De novo seven extra repeat expanded mutation in the PRNP gene in an Italian patient with early onset dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2007, 78, 1411-1413.	0.9	8
133	Reduced activity of cortico-striatal fibres in the R6/2 mouse model of Huntington's disease. NeuroReport, 2007, 18, 1997-2000.	0.6	12
134	Deletions in CCM2 Are a Common Cause of Cerebral Cavernous Malformations. American Journal of Human Genetics, 2007, 80, 69-75.	2.6	80
135	Highly variable penetrance in subjects affected with cavernous cerebral angiomas (CCM) carrying novel CCM1 and CCM2 mutations. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2007, 144B, 691-695.	1.1	32
136	Low brain-derived neurotrophic factor (BDNF) levels in serum of Huntington's disease patients. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2007, 144B, 574-577.	1.1	142
137	The Relationship Between CAG Repeat Length and Age of Onset Differs for Huntington's Disease Patients with Juvenile Onset or Adult Onset. Annals of Human Genetics, 2007, 71, 295-301.	0.3	110
138	The platelet maximum number of A2A-receptor binding sites (Bmax) linearly correlates with age at onset and CAG repeat expansion in Huntington's disease patients with predominant chorea. Neuroscience Letters, 2006, 393, 27-30.	1.0	35
139	Genome-wide significance for a modifier of age at neurological onset in Huntington's Disease at 6q23-24: the HD MAPS study. BMC Medical Genetics, 2006, 7, 71.	2.1	72
140	Genotype-dependent priming to self- and xeno-cannibalism in heterozygous and homozygous lymphoblasts from patients with Huntington's disease. Journal of Neurochemistry, 2006, 98, 1090-1099.	2.1	31
141	The search for cerebral biomarkers of Huntington's disease: a review of genetic models of age at onset prediction. European Journal of Neurology, 2006, 13, 408-415.	1.7	15
142	Increased apoptosis, huntingtin inclusions and altered differentiation in muscle cell cultures from Huntington's disease subjects. Cell Death and Differentiation, 2006, 13, 2068-2078.	5.0	81
143	Severe ultrastructural mitochondrial changes in lymphoblasts homozygous for Huntington disease mutation. Mechanisms of Ageing and Development, 2006, 127, 217-220.	2.2	85
144	Huntingtin fragmentation and increased caspase 3, 8 and 9 activities in lymphoblasts with heterozygous and homozygous Huntington's disease mutation. Mechanisms of Ageing and Development, 2006, 127, 213-216.	2.2	35

#	Article	IF	Citations
145	Juvenile Huntington's disease: Does a dosage-effect pathogenic mechanism differ from the classical adult disease?. Mechanisms of Ageing and Development, 2006, 127, 208-212.	2.2	62
146	Low frequency of PDCD10 mutations in a panel of CCM3 probands: potential for a fourth CCM locus. Human Mutation, 2006, 27, 118-118.	1.1	98
147	DJ-1 Transcriptionally Up-regulates the Human Tyrosine Hydroxylase by Inhibiting the Sumoylation of Pyrimidine Tract-binding Protein-associated Splicing Factor. Journal of Biological Chemistry, 2006, 281, 20940-20948.	1.6	162
148	Brain white-matter volume loss and glucose hypometabolism precede the clinical symptoms of Huntington's disease. Journal of Nuclear Medicine, 2006, 47, 215-22.	2.8	201
149	New Huntington disease mutation arising from a paternal CAG34allele showing somatic length variation in serially passaged lymphoblasts. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2005, 133B, 127-130.	1.1	9
150	Adenosine A2A receptor dysfunction correlates with age at onset anticipation in blood platelets of subjects with Huntington's disease. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2005, 139B, 101-105.	1.1	31
151	Novel parkin mutations detected in patients with early-onset Parkinson's disease. Movement Disorders, 2005, 20, 424-431.	2.2	60
152	Ataxia with isolated vitamin E deficiency: neurological phenotype, clinical follow-up and novel mutations in TTPAgene in Italian families. Neurological Sciences, 2004, 25, 130-137.	0.9	131
153	The gender effect in juvenile Huntington disease patients of Italian origin. American Journal of Medical Genetics Part A, 2004, 125B, 92-98.	2.4	41
154	DJ-1(PARK7), a novel gene for autosomal recessive, early onset parkinsonism. Neurological Sciences, 2003, 24, 159-160.	0.9	363
155	Italian Huntington disease patients-data and tissue bank. Neurological Sciences, 2003, 24, 215-216.	0.9	5
156	Predictive testing for persons at risk for homozygosity for CAG expansion in the Huntington disease gene. Clinical Genetics, 2003, 64, 524-525.	1.0	11
157	Highly disabling cerebellar presentation in Huntington disease. European Journal of Neurology, 2003, 10, 443-444.	1.7	19
158	Mutations in the DJ-1 Gene Associated with Autosomal Recessive Early-Onset Parkinsonism. Science, 2003, 299, 256-259.	6.0	2,467
159	Mutations in a Gene Encoding a Novel Protein Containing a Phosphotyrosine-Binding Domain Cause Type 2 Cerebral Cavernous Malformations. American Journal of Human Genetics, 2003, 73, 1459-1464.	2.6	319
160	Homozygosity for CAG mutation in Huntington disease is associated with a more severe clinical course. Brain, 2003, 126, 946-955.	3.7	173
161	The DJ-1L166P mutant protein associated with early onset Parkinson's disease is unstable and forms higher-order protein complexes. Human Molecular Genetics, 2003, 12, 2807-2816.	1.4	128
162	Aberrant A 2A receptor function in peripheral blood cells in Huntington's disease. FASEB Journal, 2003, 17, 1-16.	0.2	75

#	Article	IF	Citations
163	Localization of autosomal recessive early-onset parkinsonism to chromosome 1p36 (PARK7) in an independent dataset. Annals of Neurology, 2002, 51, 253-256.	2.8	74
164	Autosomal recessive early onset parkinsonism is linked to three loci: PARK2, PARK6, and PARK7. Neurological Sciences, 2002, 23, s59-s60.	0.9	40
165	CAG mutation effect on rate of progression in Huntington's disease. Neurological Sciences, 2002, 23, s107-s108.	0.9	24
166	The prolonged cortical silent period in patients with Huntington's disease. Clinical Neurophysiology, 2001, 112, 1470-1474.	0.7	52
167	Onset and pre-onset studies to define the Huntingtonâ€™s disease natural history. Brain Research Bulletin, 2001, 56, 233-238.	1.4	43
168	Loss of normal huntingtin function: new developments in Huntington's disease research. Trends in Neurosciences, 2001, 24, 182-188.	4.2	341
169	Presymptomatic tests in Huntington's disease and dominant ataxias. Neurological Sciences, 2001, 22, 55-56.	0.9	27
170	Atypical movement disorders in the early stages of Huntington's disease: clinical and genetic analysis. Clinical Genetics, 2001, 58, 50-56.	1.0	72
171	Mutation of thePRNP gene at codon 211 in familial Creutzfeldt-Jakob disease. American Journal of Medical Genetics Part A, 2001, 103, 133-137.	2.4	16
172	Cavernous angiomas of the nervous system in Italy: clinical and genetic study. Neurological Sciences, 2000, 21, 129-134.	0.9	11
173	Analysis of (CAG)n size heterogeneity in somatic and sperm cell DNA from intermediate and expanded Huntington disease gene carriers. , 1997, 10, 458-464.		27
174	Update on genetics of Huntington's disease: availability of direct and accurate predictive test. Italian Journal of Neurological Sciences, 1996, 17, 185-187.	0.1	4
175	Somatic mosaicism in sperm is associated with intergenerational (CAG)n changes in Huntington disease. Human Molecular Genetics, 1995, 4, 189-195.	1.4	74
176	Polymorphism analysis of the huntingtin gene in Italian families affected with Huntington disease. Human Molecular Genetics, 1994, 3, 1129-1132.	1.4	32
177	A Worldwide Study of the Huntington's Disease Mutation: The Sensitivity and Specificity of Measuring CAG Repeats. New England Journal of Medicine, 1994, 330, 1401-1406.	13.9	563
178	DNA haplotype analysis of Huntington disease reveals clues to the origins and mechanisms of CAG expansion and reasons for geographic variations of prevalence. Human Molecular Genetics, 1994, 3, 2103-2114.	1.4	178
179	The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease. Nature Genetics, 1993, 4, 398-403.	9.4	1,002
180	Molecular analysis of new mutations for Huntington's disease: intermediate alleles and sex of origin effects. Nature Genetics, 1993, 5, 174-179.	9.4	248

#	Article	IF	Citations
181	Molecular analysis of juvenile Huntington disease: the major influence on (CAG)n repeat length is the sex of the affected parent. Human Molecular Genetics, 1993, 2, 1535-1540.	1.4	189
182	Suicide risk in Huntington's disease.. Journal of Medical Genetics, 1993, 30, 293-295.	1.5	118
183	Onset symptoms in 510 patients with Huntington's disease.. Journal of Medical Genetics, 1993, 30, 289-292.	1.5	60
184	Molecular analysis of late onset Huntington's disease.. Journal of Medical Genetics, 1993, 30, 991-995.	1.5	57
185	Familial predisposition to recurrent mutations causing Huntington's disease: genetic risk to sibs of sporadic cases.. Journal of Medical Genetics, 1993, 30, 987-990.	1.5	34
186	A Double-Blind Cross-over Trial of Amantadine Hydrochloride in Friedreich's Ataxia. Canadian Journal of Neurological Sciences, 1993, 20, 52-55.	0.3	27
187	Genetic linkage analysis and presymptomatic testing in Huntington's disease. First report in Italy. Acta Neurologica, 1992, 14, 524-9.	0.1	0